Fighting diseases of poverty: Drugs for Neglected Diseases Initiative (DNDi)
As one of the leading Product Development Partnerships (PDPs) worldwide, DNDi is acting in the public interest and to respond to patients’ needs to develop and provide access to treatments for neglected tropical diseases that primarily affect the poor and marginalised populations worldwide. DNDi’s business model is further characterized by empowerment of endemic country partners, international advocacy in support of a global framework for essential health, and delivery of health tools as public goods.
| Pays/région | Thème | Période | Budget |
|---|---|---|---|
|
Monde entier |
Santé
Maladies infectieuses
Renforcement des systèmes de santé Maladies sexuellement transmissibles (y compris VIH/sida) |
01.01.2013
- 31.12.2016 |
CHF 8’000’000
|
- Outcome 1: Five treatment optimisations are developed, rationally used, and better accessed.
- Outcome 2: Innovative treatments for HAT, leishmaniasis, Chagas disease, filarial diseases and HIV-TB co-infected children are developed.
- Outcome 3: Endemic countries capacities strengthened and technology transfer achieved.
- Outcome 4: Awareness about the need to develop new drugs for NTDs raised internationally.
- Three new treatments or set of treatments registered or recommended for visceral leishmaniasis and Chagas disease.
- Increased distribution and use of three treatments for malaria and sleeping sickness facilitated
- An increasing number of drug candidates progressed at clinical stage.
- Research platforms to mobilise scientists, clinicians, research and international organizations, NGOs, national control programmes, health ministries, regulatory authorities, and private-sector actors.
- Autre organisation suisse non-profit
- DNDi
-
Secteur selon catégorisation du Comité d'aide au développement de l'OCDE SANTE
SANTE
POLITIQUE EN MATIERE DE POPULATION/SANTE & FERTILITE
Sous-Secteur selon catégorisation du Comité d'aide au développement de l'OCDE Lutte contre les maladies infectieuses
Politique de la santé et gestion administrative
Lutte contre les MST et VIH/sida
Thème transversal Le projet tient compte de l'égalité des sexes en tant que thème transversal.
Le projet contribue à améliorer le fonctionnement de l'organisation partenaire
Type de soutien Aide publique au développement (APD)
Type de collaboration Coopération bilatérale
Type de financement Don
Type d'aide Contribution de base
Aide liée/non liée Aide non liée
Numéro de projet 7F07741
| Contexte |
DNDi is one of the few and most successful public private partnerships that seek to coordinate the contributions of the private, public, academic and not-for-profit sectors to address the scientific, economic, legal and political challenges that exist in developing new health technologies for the use in developing countries, and in ensuring their rapid and widespread use. |
| Objectifs |
DNDi’s primary objective is to deliver 11 to 13 new treatments by 2018 for leishmaniasis, human African trypanosomiasis (sleeping sickness), Chagas disease, malaria, paediatric HIV, and specific helminth infections and to establish a strong R&D portfolio that addresses patients’ treatment needs and supports long term objectives. Moreover, further objectives include using and strengthening existing capacities in disease-endemic countries via project implementation and raising awareness about the need to develop new drugs for neglected diseases and advocate for increased public responsibility. |
| Groupes cibles |
More than 1 billion people worldwide affected by NTDs, mainly in Africa and mostly those living in remote rural areas, urban slums or conflict zones. |
| Effets à moyen terme |
|
| Résultats |
Principaux résultats antérieurs: |
| Direction/office fédéral responsable |
DDC |
| Crédit |
Coopération au développement |
| Partenaire de projet |
Partenaire contractuel Organisation suisse à but non lucratif |
| Budget | Phase en cours Budget de la Suisse CHF 8’000’000 Budget suisse déjà attribué CHF 8’000’000 |
| Phases du projet |
Phase
4
01.01.2021
- 31.12.2024
(Phase en cours)
Phase 3
01.01.2017
- 31.12.2020
(Completed)
Phase 2 01.01.2013 - 31.12.2016 (Completed) |
